Salem AH - Search Results

1

Venetoclax in combination with cytarabine with or without idarubicin in children with relapsed or refractory acute myeloid leukaemia: a phase 1, dose-escalation study.

Karol SE, Alexander TB, Budhraja A, Pounds SB, Canavera K, Wang L, Wolf J, Klco JM, Mead PE, Das Gupta S, Kim SY, Salem AH, Palenski T, Lacayo NJ, Pui CH, Opferman JT, Rubnitz JE. Karol SE, et al. Among authors: salem ah. Lancet Oncol. 2020 Apr;21(4):551-560. doi: 10.1016/S1470-2045(20)30060-7. Epub 2020 Mar 11. Lancet Oncol. 2020. PMID: 32171069 Free PMC article. Clinical Trial.

2

Evaluation of Rifampin's Transporter Inhibitory and CYP3A Inductive Effects on the Pharmacokinetics of Venetoclax, a BCL-2 Inhibitor: Results of a Single- and Multiple-Dose Study.

Agarwal SK, Hu B, Chien D, Wong SL, Salem AH. Agarwal SK, et al. Among authors: salem ah. J Clin Pharmacol. 2016 Nov;56(11):1335-1343. doi: 10.1002/jcph.730. J Clin Pharmacol. 2016. PMID: 26953185 Clinical Trial.

3

Effect of Low- and High-Fat Meals on the Pharmacokinetics of Venetoclax, a Selective First-in-Class BCL-2 Inhibitor.

Salem AH, Agarwal SK, Dunbar M, Nuthalapati S, Chien D, Freise KJ, Wong SL. Salem AH, et al. J Clin Pharmacol. 2016 Nov;56(11):1355-1361. doi: 10.1002/jcph.741. J Clin Pharmacol. 2016. PMID: 27029823 Clinical Trial.

4

Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia.

Konopleva M, Pollyea DA, Potluri J, Chyla B, Hogdal L, Busman T, McKeegan E, Salem AH, Zhu M, Ricker JL, Blum W, DiNardo CD, Kadia T, Dunbar M, Kirby R, Falotico N, Leverson J, Humerickhouse R, Mabry M, Stone R, Kantarjian H, Letai A. Konopleva M, et al. Among authors: salem ah. Cancer Discov. 2016 Oct;6(10):1106-1117. doi: 10.1158/2159-8290.CD-16-0313. Epub 2016 Aug 12. Cancer Discov. 2016. PMID: 27520294 Free PMC article. Clinical Trial.

5

Pharmacokinetics of Venetoclax, a Novel BCL-2 Inhibitor, in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Non-Hodgkin Lymphoma.

Salem AH, Agarwal SK, Dunbar M, Enschede SL, Humerickhouse RA, Wong SL. Salem AH, et al. J Clin Pharmacol. 2017 Apr;57(4):484-492. doi: 10.1002/jcph.821. Epub 2016 Nov 15. J Clin Pharmacol. 2017. PMID: 27558232

6

Venetoclax does not prolong the QT interval in patients with hematological malignancies: an exposure-response analysis.

Freise KJ, Dunbar M, Jones AK, Hoffman D, Enschede SL, Wong S, Salem AH. Freise KJ, et al. Among authors: salem ah. Cancer Chemother Pharmacol. 2016 Oct;78(4):847-53. doi: 10.1007/s00280-016-3144-1. Epub 2016 Sep 1. Cancer Chemother Pharmacol. 2016. PMID: 27586967

7

Impact of Venetoclax Exposure on Clinical Efficacy and Safety in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia.

Freise KJ, Jones AK, Eckert D, Mensing S, Wong SL, Humerickhouse RA, Awni WM, Salem AH. Freise KJ, et al. Among authors: salem ah. Clin Pharmacokinet. 2017 May;56(5):515-523. doi: 10.1007/s40262-016-0453-9. Clin Pharmacokinet. 2017. PMID: 27638334 Clinical Trial.

8

Effect of ketoconazole, a strong CYP3A inhibitor, on the pharmacokinetics of venetoclax, a BCL-2 inhibitor, in patients with non-Hodgkin lymphoma.

Agarwal SK, Salem AH, Danilov AV, Hu B, Puvvada S, Gutierrez M, Chien D, Lewis LD, Wong SL. Agarwal SK, et al. Among authors: salem ah. Br J Clin Pharmacol. 2017 Apr;83(4):846-854. doi: 10.1111/bcp.13175. Epub 2017 Jan 18. Br J Clin Pharmacol. 2017. PMID: 27859472 Free PMC article. Clinical Trial.

9

Evaluation of the Pharmacokinetic Interaction between Venetoclax, a Selective BCL-2 Inhibitor, and Warfarin in Healthy Volunteers.

Salem AH, Hu B, Freise KJ, Agarwal SK, Sidhu DS, Wong SL. Salem AH, et al. Clin Drug Investig. 2017 Mar;37(3):303-309. doi: 10.1007/s40261-016-0485-9. Clin Drug Investig. 2017. PMID: 27910036 Clinical Trial.

10

Relationship between venetoclax exposure, rituximab coadministration, and progression-free survival in patients with relapsed or refractory chronic lymphocytic leukemia: demonstration of synergy.

Freise KJ, Jones AK, Menon RM, Verdugo ME, Humerickhouse RA, Awni WM, Salem AH. Freise KJ, et al. Among authors: salem ah. Hematol Oncol. 2017 Dec;35(4):679-684. doi: 10.1002/hon.2373. Epub 2016 Dec 16. Hematol Oncol. 2017. PMID: 27982454

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

294 results

Search Page